Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study
Gemcitabine is a key drug for the treatment of pancreatic cancer; however, with its limitation in clinical benefits, the development of another potent therapeutic is necessary. Vascular endothelial growth factor receptor 2 is an essential target for tumor angiogenesis, and we have conducted a phase...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
John Wiley & Sons, Ltd
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520640/ |